Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by…
You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was founded in 1995. The…
Over ten years ago, the economic concept of the ‘BRIC’ countries- Brazil, Russia, India and China – was formed, and it’s pretty much all we’ve heard about ever since.…
Despite being in the Mexican market for over twenty years, biosimilars have never been regulated as a separate entity. They have always been regulated as simply another category of generic…
We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes…
First of all, can you tell us about the history of Andromaco and what have been its major milestones and challenges over the years? This year marks the eightieth anniversary…
Gelpharma started in 1999 and its main strength lies in manufacturing. Please can you give us a more detailed history of the company and its major milestones since opening? We…
First of all, congratulations on the new distribution warehouse in Lerma, State of Mexico . You mentioned that there were two more to come: can you give us a bit…
The company Cryopharma was founded in 1954 with 10 employees. Today, you have fantastic facilities here in the state of Jalisco, and have grown the company to an entire group…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified…
Mexico is number one in child obesity and number two in adult obesity in the world. This is one of the reasons that diabetes is rapidly increasing and the Mexican…
See our Cookie Privacy Policy Here
